GIST

Quiz: Which SOC Treatment is an Alternative for Imatinib Intolerant Advanced, mGIST?
11/16/2021
Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.
Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.
Approved globally, _______ is...
11/16/2021
Oncology
Sunitinib Displays Safety, Efficacy for Imatinib-Resitant Patients with Advanced GIST
11/15/2021
A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.
A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.
A real-world study confirms...
11/15/2021
Oncology
Imatinib Exhibits Viability as Neoadjuvant Therapy for GIST
11/15/2021
Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.
Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.
Imatinib is found feasible as...
11/15/2021
Oncology
Conference Coverage
Dose Escalation of Ripretinib Yields OR in Tumor Progressive GIST
11/15/2021
Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.
Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.
Investigators sought to evaluate...
11/15/2021
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
Conference Coverage
Driver Mutations Found Targetable for Wild-Type GIST
09/14/2021
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Findings from a recent study...
09/14/2021
Oncology
Conference Insider
Phase 3 INVICTUS Trial Demonstrates Ripretinib Benefit in GIST
09/14/2021
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Mature data released from the...
09/14/2021
Oncology
Dr Coleman Talks WES of Tumor Tissue, ctDNA in GIST
Videos
Dr Coleman Talks WES of Tumor Tissue, ctDNA in GIST
04/26/2021
Niamh Coleman, MD, PhD, discusses data on whole exome sequencing (WES) of tumor tissue and ctDNA in GIST, presented at the AACR Annual Meeting.
Niamh Coleman, MD, PhD, discusses data on whole exome sequencing (WES) of tumor tissue and ctDNA in GIST, presented at the AACR Annual Meeting.
Niamh Coleman, MD, PhD,...
04/26/2021
Oncology
Conference Insider
Genetic Diagnosis Yields Benefit in GIST Therapy
04/20/2021
A patient case study, presented at the 2021 ONS Congress, supports the confirmation that a genetic diagnosis leads to the appropriate management and surveillance approach in GIST, NF1 and other comorbidities, detects the possibility for other...
A patient case study, presented at the 2021 ONS Congress, supports the confirmation that a genetic diagnosis leads to the appropriate management and surveillance approach in GIST, NF1 and other comorbidities, detects the possibility for other...
A patient case study, presented...
04/20/2021
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use